Sign In
Buy ANAB
$53.36
-1.68 (-3.05%)
At Close: Jul 31, 2026
AnaptysBio Stock Down as Eczema Study Fails to Meet Goals
10:05am, Thursday, 12'th Dec 2024
Phase IIb study on ANAB's ANB032 for atopic dermatitis fails to meet goals. The company decides to discontinue any further investment in the candidate.
AnaptysBio Discontinues Investment In Eczema Candidate After Disappointing Data
02:07pm, Wednesday, 11'th Dec 2024
On Wednesday, AnaptysBio, Inc. ANAB announced that investigational ANB032, a BTLA agonist, did not meet the primary and secondary endpoints in any of the doses studied in the ARISE-AD trial as a monot
AnaptysBio to abandon eczema drug development after mid-stage trial failure
10:20am, Wednesday, 11'th Dec 2024
AnaptysBio will end the development of its experimental drug to treat eczema as the treatment failed to meet the goals of a mid-stage trial, the company said on Wednesday, dragging its shares nearly 4
AnaptysBio abandons eczema drug development after mid-stage trial failure
08:42am, Wednesday, 11'th Dec 2024
AnaptysBio said on Wednesday that it would discontinue the development of its eczema drug after it failed to meet the main and secondary goals of a mid-stage trial.
Anaptys Announces Phase 2b Trial of ANB032, a BTLA Agonist, Did Not Meet Primary or Secondary Endpoints in Atopic Dermatitis
08:30am, Wednesday, 11'th Dec 2024
SAN DIEGO, Dec. 11, 2024 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today announced that inve
Are Medical Stocks Lagging AnaptysBio (ANAB) This Year?
10:41am, Monday, 25'th Nov 2024
Here is how AnaptysBio, Inc. (ANAB) and Castle Biosciences, Inc. (CSTL) have performed compared to their sector so far this year.
AnaptysBio (ANAB) Upgraded to Buy: What Does It Mean for the Stock?
01:01pm, Friday, 08'th Nov 2024
AnaptysBio (ANAB) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Down -32.84% in 4 Weeks, Here's Why You Should You Buy the Dip in AnaptysBio (ANAB)
10:36am, Friday, 08'th Nov 2024
The heavy selling pressure might have exhausted for AnaptysBio (ANAB) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts
AnaptysBio, Inc. (ANAB) Reports Q3 Loss, Tops Revenue Estimates
06:30pm, Tuesday, 05'th Nov 2024
AnaptysBio, Inc. (ANAB) came out with a quarterly loss of $1.14 per share versus the Zacks Consensus Estimate of a loss of $1.72. This compares to loss of $1.41 per share a year ago.
Anaptys Announces Participation in November and December Investor Conferences
04:15pm, Tuesday, 05'th Nov 2024
SAN DIEGO, Nov. 05, 2024 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today announced that Dani
Anaptys Announces Third Quarter 2024 Financial Results and Provides Business Update
04:15pm, Tuesday, 05'th Nov 2024
SAN DIEGO, Nov. 05, 2024 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today reported financial
Anaptys Announces Participation in September Investor Conferences
09:15am, Thursday, 29'th Aug 2024
SAN DIEGO, Aug. 29, 2024 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today announced that Dani
Why AnaptysBio Was Such a Healthy Stock This Week
07:26am, Friday, 23'rd Aug 2024
The biotech saw some action thanks in no small part to a new analyst note. This reiterated an existing buy recommendation at a relatively high target price.
AnaptysBio: Top-Line AD Data End Of 2024 Could Be Turning Point
02:14pm, Thursday, 15'th Aug 2024
AnaptysBio, Inc. 14-week results from the phase 2b study, using ANB032 for the treatment of patients with moderate-to-severe Atopic Dermatitis, expected in December 2024. The global Atopic dermatitis
Anaptys Announces Pricing of $100 Million Underwritten Registered Direct Offering
05:00am, Wednesday, 14'th Aug 2024
Led by long-standing investor EcoR1 Capital with participation from additional existing and new investors, including Sanofi Led by long-standing investor EcoR1 Capital with participation from addition
